High interest

Galvanize Therapeutics reports a $136.2M equity raise from 26 investors, including $130M in new money; no broker listed

Form type
Form D (new notice) Reg D Rule 506(b)
Amount
$136,185,232 sold to 26 investors; offering fully sold
Investors
26
First sale
Nov 6, 2026
Filed
Nov 18, 2026, 2:02 PM ET

Galvanize Therapeutics, Inc., a Redwood City, California biotechnology company formerly known as Gala Therapeutics, filed a new Form D on Wednesday reporting a fully sold $136.2 million equity offering to 26 investors. The filing says about $130.0 million is new money and $6.2 million came from converting debt. The first sale was on Nov. 6, and no broker or sales compensation is listed.

What to watch

  1. $136.2M equity offering, fully sold to 26 investors
  2. About $130.0M new money and $6.2M debt conversion, per the filing
  3. First sale Nov. 6, 2026; Rule 506(b)
  4. No broker or sales compensation listed
  5. Company previously filed as Gala Therapeutics and has earlier Form Ds from 2019, 2022 and 2025

Market context

The filing comes on a mixed day for U.S. stocks, with the S&P 500 down 0.2% for a fifth straight loss, the Dow off 1.1% and the Nasdaq up 0.4%.

View filing on DisclosureQuest →

Opens the filing on disclosurequest.com

Share this filing

Offering amounts are maximums, not money raised. Source: SEC EDGAR via DisclosureQuest. © 2026 Crowded Media Group, LLC. All rights reserved.